Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (4124)	12/31/1997 12:17:00 AM
From: DAVID	Read Replies (1) \| Respond to of 23519

To: Blankmind I like the letter. It was quite professional in tone. Please post the address to the editor at Barrons, I will send them a statement myself and I don't think it will be quite as professional as yours. After I send my letter, I will send them a well bloated hog shipped by UPS from my friends hog farm. When it arrives, I'm sure it will make the editor a nice happy new years present and dinner. I'm a long term Vivus investor and a biotechnology consultant.

To: blankmind who wrote (4124)	12/31/1997 12:25:00 AM
From: BigKNY3	Read Replies (2) \| Respond to of 23519

Blankmind: I was never able to find any MUSE clinical study in which Dr. Irwin Goldstein ever participated. It is difficult to understand why Vivus never involved this influential and outspoken ED investigator in evaluating MUSE. He has one of the most important ED clinics in the world and was a co-author of the classic "Massachusetts Male Aging Study" published in 1994. I agree with you that Barron's should have brought this up in their interview. BigKNY3